<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02157571</url>
  </required_header>
  <id_info>
    <org_study_id>Prulifloxacin AECB ZK-004</org_study_id>
    <nct_id>NCT02157571</nct_id>
  </id_info>
  <brief_title>A Multi-center, Randomized, Double-blind, Double-dummy Clinical Study to Evaluate the Safety and Efficacy of Prulifloxacin Film-coated Tablet for the Treatment of Acute Exacerbations of Chronic Bronchitis With Levofloxacin Hydrochloride Tablet as Active Control</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lee's Pharmaceutical Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lee's Pharmaceutical Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to use oral prulifloxacin to treat patient with Acute&#xD;
      Exacerbations of Chronic Bronchitis and compare the effect with Levofloxacin.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the efficacy and safety of prulifloxacin film-coated tablet in the treatment of acute exacerbations of chronic bronchitis.</measure>
    <time_frame>7-10 days</time_frame>
    <description>Clinical efficacy: consists of clinical evaluation which expressed as clinical cure and clinical failure.&#xD;
Bacteriological efficacy: consists of eradication, supposed eradication, persistence, supposed persistence, partial eradication,;&#xD;
Comprehensive therapeutic efficacy: consists of cure and failure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety of treatment</measure>
    <time_frame>7-10 days</time_frame>
    <description>Vital signs, ECG, laboratory examinations and adverse events.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Acute Exacerbations of Chronic Bronchitis</condition>
  <arm_group>
    <arm_group_label>Prulifloxacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prulifloxacin film-coated tablet : 600 mg/tablet, oral administration of a single tablet.&#xD;
Placebo of levofloxacin hydrochloride tablet, without active components.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levofloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Levofloxacin hydrochloride tablet 500 mg/tablet, oral administration of a tablet daily.&#xD;
Placebo of prulifloxacin film-coated tablet without active components.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prulifloxacin</intervention_name>
    <description>600 mg/tablet, oral administration of a single tablet.</description>
    <arm_group_label>Prulifloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin</intervention_name>
    <description>500 mg/tablet, oral administration of a tablet daily.</description>
    <arm_group_label>Levofloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin Placebo</intervention_name>
    <description>Placebo of levofloxacin hydrochloride tablet, without active components.</description>
    <arm_group_label>Prulifloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prulifloxacin placebo</intervention_name>
    <description>Placebo of prulifloxacin film-coated tablet without active components.</description>
    <arm_group_label>Levofloxacin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient is willing to participate in the study and gives the signature of informed&#xD;
             consent;&#xD;
&#xD;
          2. In and out-patients (aged 18-70 years old), male or female;&#xD;
&#xD;
          3. Patient receives no effective antibacterial therapy or the therapy has no remarkable&#xD;
             efficacy, or positive bacterial test result in the past 72 hours;&#xD;
&#xD;
          4. Diagnosed as mild to moderate acute exacerbation of chronic bronchitis patients (see&#xD;
             &lt;Severity Evaluation Criteria Table&gt;)&#xD;
&#xD;
          5. Within 48 hours prior to the study, women of child-bearing age have a negative urine&#xD;
             pregnancy test and is willing to use efficient measures of contraception to avoid&#xD;
             pregnancy during the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient hypersensitive to quinolones or with allergic constitution;&#xD;
&#xD;
          2. Patient with severe condition which need combination with other antibacterial agents;&#xD;
&#xD;
          3. Concurrent infections in other organs or system;&#xD;
&#xD;
          4. Patient with severe heart, liver or kidney disease, or Q-T prolongation of over 450&#xD;
             ms, serum AST or ALT more than twice as high as the upper limit of normal or Cr over&#xD;
             the upper limit of normal;&#xD;
&#xD;
          5. With any of the following diseases: active tuberculosis, bronchiectasis, lung abscess,&#xD;
             aspiration pneumonia, lung cancer, non-infectious interstitial lung disease, pulmonary&#xD;
             edema, atelectasis, pulmonary embolism, pulmonary addicted acidic granulocyte&#xD;
             infiltration and pulmonary vasculitis syndrome;&#xD;
&#xD;
          6. Patient with severe hematologic disease or central nervous system disease or&#xD;
             convulsion history, with mental status unable to coordinate;&#xD;
&#xD;
          7. Patient with malignant tumor or other severe background disease;&#xD;
&#xD;
          8. Patient with severe immunodeficiency;&#xD;
&#xD;
          9. A history of tendon;&#xD;
&#xD;
         10. Known pregnancy or lactation;&#xD;
&#xD;
         11. Prulifloxacin contains lactose, therefore, patients with a rare genetic disease such&#xD;
             as galactose intolerance, Lapp lactase deficiency or glucose - galactose malabsorption&#xD;
             cannot be enrolled;&#xD;
&#xD;
         12. Participation in other clinical trials within 3 months before screening or currently&#xD;
             on any investigational therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nei Mongo medical University</name>
      <address>
        <city>Nei Mongo</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liying Cui, Doctor</last_name>
      <phone>+86-471-6637524</phone>
    </contact>
    <investigator>
      <last_name>Liying Cui, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>June 4, 2014</study_first_submitted>
  <study_first_submitted_qc>June 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2014</study_first_posted>
  <last_update_submitted>June 5, 2014</last_update_submitted>
  <last_update_submitted_qc>June 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prulifloxacin</keyword>
  <keyword>AECB</keyword>
  <keyword>Levofloxacin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchitis</mesh_term>
    <mesh_term>Bronchitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Prulifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

